A new study reveals that the common anti-obesity medicines such as topiramate and phentermine used in combination or individually can help the patients to lose weight. They are particularly helpful for patients who lost weight after having Roux-en-Y gastric bypass surgery. The findings of the retrospective study are now published in journal Obesity, the flagship journal of The Obesity Society.
Nawfal Istfan from the Boston University School of Medicine and an attending physician at Boston Medical Center is the corresponding author of the study. He says that this new study could be extremely beneficial for certain people who are not ordinary weight loss patients.
A weight re-gain after going through a gastric surgery is common takes place within the two years of getting the surgery. It affects nearly 25% of all the patients which is why it is necessary to keep a check on the patients after this surgery. Maintaining and preserving the medical benefits of losing weight are a prime advises that a doctor typically gives to such a patient. the use of weight loss supplements during such a situation might not work, as their is limited scientific data on its efficacy.
while studying this, the research team used the e-records of the clinics by extracting some 1200 patients of different ethnicities who used Roux-en-Y gastric bypass surgery at Boston Medical Center. The time period where all these patients received this surgery was somewhat between 2004 and 2015.
The re-evaluation of the weight was performed by comparing the new weight of every patient during the post-operative period when he visited the doctor’s office. The time period for this re-evaluation of the weight was spread to six years after the surgery was performed.
Some of these patients were prescribed anti-obesity medicines during their follow-up checkups after the surgery and added to a category called ‘adherent’ people. Those who didn’t show up for this follow up were added into a category of “nonadherent” people.
These outcomes reveal that the patients usually lost their weight by taking anti-obesity supplements. However, they gained it all back during the intervals when no medications were prescribed. Moreover, patients started using anti-obesity drugs at different time periods.
The authors of the study highlight the true potential of topiramate and phentermine and other anti-obesity medicine to prevent re-gaining the weight and comorbidities related to obesity that should be checked in detail in clinical trials in near future.
Crystal Johnson-Mann from the University of Florida College Of Medicine commented on this study that these limitations need to be addressed properly so that the use of these anti-obesity medicines could be controlled. By providing awareness, education, and training to people as well as medical practitioners as per the nature and working of these anti-obesity supplements could help to prevent the recurrene of obesity.
This aspect is perfect for an in-depth clinical trial where people with specific tendencies should b checked for using these medicines. Only the research and trials could explain how effective these obesity medicines are for the patients.